Read + Share
Michallet AS, Letestu R, Le Garff-Tavernier M, Aanei C, et al. A fixed-duration, measurable residual disease-guided approach in CLL: follow-up
data from the phase 2 ICLL-07 FILO trial. Blood 2021;137:1019-1023.
PMID: 33167024
|
 |
|
Michallet AS, Letestu R, Le Garff-Tavernier M, Aanei C, et al. A fixed-duration, measurable residual disease-guided approach in CLL: follow-up
data from the phase 2 ICLL-07 FILO trial. Blood 2021;137:1019-1023.
PMID: 33167024
|
|
|
|